Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of California, San Francisco
With
Thrasher Research Fund
UCSF Benioff Children's Hospital Oakland
University of Washington
Santa Clara Valley Health & Hospital System
Newborn infants with birth asphyxia are at high risk of death or long-term neurologic disability; yet therapies for birth asphyxia are currently limited. Erythropoietin (Epo) is a FDA-approved drug that is an effective neuroprotective agent in animal models of birth asphyxia. This is a phase I dose finding multi-center trial that will test the safety and pharmacokinetics of Epo in human infants with birth asphyxia. The long-term objectives of the proposed research are to reduce mortality and to decrease the risk of long-term disabilities in infants who survive beyond the newborn period.
Age
0–0
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. ≥ 36 weeks gestational age
2. Perinatal depression (low Apgar score, need for resuscitation)
